Ameriprise
SGP

Ameriprise’s SpyGlass Pharma SGP Stock Holding History

Ameriprise’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
45,668
+1,191
+3% +$25.8K ﹤0.01% 3389
2026
Q1 		$1.15M Buy
+44,477
New +$1.2M ﹤0.01% 3230

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ameriprise's SGP Position: Q2 2026 in Review

Ameriprise increased its SpyGlass Pharma (SGP) stake by 2.7% in Q2 2026, buying an estimated $25.8K and bringing the position to 45,668 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

Ameriprise first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.15M in Q1 2026. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Ameriprise held 45,668 shares of SpyGlass Pharma worth $1.02M as of Q2 2026.
  • Ameriprise bought 1,191 SpyGlass Pharma shares in Q2 2026, an estimated $25.8K.
  • SpyGlass Pharma made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3389 holding.
  • Ameriprise first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • Ameriprise's SpyGlass Pharma position peaked at $1.15M in Q1 2026.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.